GIF partners with Reme.D to scale affordable medical testing.

We are proud to announce that GIF is providing a $500,000 equity investment in Reme.D, an Egyptian biotech company manufacturing locally produced, room-temperature-stable medical test kits designed for health settings across Africa and the Middle East.

Closing the diagnostics access gap

Across Africa, diagnostic capacity remains severely constrained. Only about 30% of health facilities have the tools needed for basic testing, with availability falling to just 19% at the primary care level where most patients first seek care. For communicable diseases such as HIV, tuberculosis, and hepatitis, this gap directly translates into delayed diagnoses, missed treatment windows, and preventable deaths.

Imported medical tests are often unaffordable or unreachable. High costs, dependence on continuous cold chains, and designs optimised for well-resourced laboratories have kept high-accuracy testing out of reach in the settings that need it most. Reme.D was founded to change that.

Innovation that lowers barriers to care

Reme.D designs and manufactures its diagnostic kits locally in Cairo, drawing on proprietary nanotechnology and freeze-drying techniques that allow its testing components to remain effective at temperatures above 30°C without refrigeration. By removing the need for constant refrigeration in markets where electricity is unreliable, the technology eliminates wastage and emergency procurement delays that disrupt traditional diagnostic services in these regions. 

Reme.D offers testing at one-quarter of the price of imported alternatives. Their product suite  covers 30 infectious and non-communicable diseases, utilising mobile testing units capable of bringing vital diagnostic power to remote areas and emergency settings. 

Building climate and health system resilience

Reme.D's model is a direct response to the increasing challenges at the intersection of climate change and global health. As climate-sensitive diseases including dengue, Zika, and monkeypox spread into new geographies, and as extreme weather makes cold chain logistics increasingly fragile, the need for diagnostics that function reliably in high-temperature, low-infrastructure settings becomes more urgent. By decoupling molecular diagnostic capacity from refrigeration and stable power supply, Reme.D strengthens health system resilience against both climate-induced supply shocks and the rising burden of climate-sensitive disease.

Reme.D's impact includes an important gender dimension. Its product suite includes tests for HPV and other women-specific conditions, and the company has been working with a government hospital in Cairo to provide free HPV screening to women from underserved communities. 

Scaling for the future

GIF's investment will support Reme.D's expansion into a new, purpose-built 2,000 sqm facility, enabling the company to significantly increase production. This expanded capacity, paired with key international regulatory certifications, will enable  Reme.D to convert a strong pipeline of opportunities to scale and strengthen health systems across Africa and the Middle East.

GIF Managing Director and deal lead, Lily Steele, said:

"We are delighted to announce our investment in Reme.D, a company that is tackling one of the most fundamental gaps in African healthcare by manufacturing high-accuracy molecular diagnostics locally, affordably, and without dependence on cold chains. Reme.D has built an impressive track record of technical innovation, commercial traction, and genuine impact and we are excited to support Salma and her team as they scale into new markets and demonstrate what homegrown African diagnostics can achieve."